Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) – Investment analysts at Leerink Swann issued their Q3 2018 earnings per share (EPS) estimates for shares of Deciphera Pharmaceuticals in a report issued on Monday, September 24th. Leerink Swann analyst A. Berens expects that the company will post earnings of ($0.64) per share for the quarter. Leerink Swann currently has a “Underperform” rating and a $28.00 target price on the stock. Leerink Swann also issued estimates for Deciphera Pharmaceuticals’ Q4 2018 earnings at ($0.75) EPS, FY2018 earnings at ($2.70) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($3.08) EPS and FY2022 earnings at ($2.39) EPS.
Other analysts have also recently issued reports about the stock. Canaccord Genuity set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 13th. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research note on Tuesday, July 24th. SunTrust Banks initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, July 5th. They issued a “buy” rating for the company. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 3rd. Finally, Cantor Fitzgerald initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, September 6th. They issued a “buy” rating and a $53.00 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $48.09.
DCPH stock opened at $38.49 on Thursday. The company has a market capitalization of $1.44 billion and a P/E ratio of -12.94. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05. Deciphera Pharmaceuticals has a 52 week low of $15.15 and a 52 week high of $45.61.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.03.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp lifted its stake in Deciphera Pharmaceuticals by 35.5% during the 2nd quarter. Northern Trust Corp now owns 114,826 shares of the company’s stock valued at $4,518,000 after acquiring an additional 30,094 shares during the period. Bank of New York Mellon Corp lifted its stake in Deciphera Pharmaceuticals by 139.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 56,442 shares of the company’s stock valued at $2,221,000 after acquiring an additional 32,878 shares during the period. Jane Street Group LLC acquired a new stake in Deciphera Pharmaceuticals during the 2nd quarter valued at approximately $1,112,000. Nexthera Capital LP acquired a new stake in Deciphera Pharmaceuticals during the 2nd quarter valued at approximately $5,108,000. Finally, Orbimed Advisors LLC lifted its stake in Deciphera Pharmaceuticals by 30.8% during the 2nd quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock valued at $78,924,000 after acquiring an additional 472,800 shares during the period. Institutional investors and hedge funds own 53.53% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
See Also: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.